Inspired by these results, two phase 1 clinical trials have started with optimized HER2-CARs for patients with HER2+ malignant glioma (NCT03389230) [293] and brain metastases of HER2+ breast cancer (NCT03696030) [294]. Here, ERBB2 is linked to breast carcinoma.